Part I: What do patients really need and want from migraine treatment?

Current Medical Research and Opinion, Supplement

Volumn 21, Issue 3, 2005, Pages

  Gendolla, Astrid ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Early treatment; Effective; Fast acting; Oral; Reliable; Triptans

Indexed keywords

ANTIMIGRAINE AGENT; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ACUTE DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG PREFERENCE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; ORALLY DISINTEGRATING TABLET; PAIN; REVIEW; TABLET DISINTEGRATION; TABLET FORMULATION;

ADMINISTRATION, ORAL; HUMANS; MIGRAINE DISORDERS; PATIENT SATISFACTION; TIME FACTORS; TRYPTAMINES;

EID: 23844481126     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X46269     Document Type: Review

References (21)

1. International Headache Society. The International Classification of Headache Disorders. (2nd Edition). Cephalagia 2004;24(Suppl 1):1-150
2. Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. Headache 1994;34:319-28
3. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation (MAZE) survey. Headache 2003;43:19-26
4. Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 1997;17:15-22
5. Clarke CE, MacMillan L, Sondhi S, et al. Economic and social impact of migraine. QJ Med 1996;89:77-84
6. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998;13:667-76
7. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159:813-18
8. Dahlöf C, Dimenas E. Migraine patients experience poorer subjective well being/quality of life even between attacks. Cephalalgia 1995;15:31-6
9. Dahlöf C. Integrating the triptans into clinical practice. Curr Opin Neurol 2002;15:317-22
10. Rapoport AM, Tepper SJ, Bigal ME, et al. The triptan formulations: how to match patients and products. CNS Drugs 2003;17:431-47
11. Celentano DD, Stewart WF, Lipton RB, et al. Medication use and disability among migraineurs: a national probability sample survey. Headache 1992;32:223-8
12. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993;43(Suppl 3): S6-S10
13. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001;41:638-45
14. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999;39(Suppl 2):S20-S26
15. MacGregor EA, Brandes J, Eikermann A, et al. Impact of Migraine on Patients and their Families. The Migraine and Zolmitriptan Evaluation [MAZE] Survey - Phase III. Curr Med Res Opin 2004;20:1143-50
16. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack: Clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000;123(Pt 8):1703-9
17. Hunter SA, Burstein S, Sedor C. Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: clinical and preclinical evidence. Headache 2002;42:390
18. International 311C90 Long-Term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. Headache 1998;38:173-83
19. Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clinical Therapeutics 2000;22: 1035-7
20. Winner P, Mannix L, McNeal S, et al. Treatment of migraine at the first sign of pain: prospective, double-blind, placebo-controlled, multicenter studies of sumatriptan 50 mg and 100 mg versus placebo. Neurology 2002;58(Suppl 3):A415
21. Klapper J, Lucas C, Røsjø Ø, et al. Benefits of treating highly-disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 2004;24:918-24